拉米夫定联合α-2b干扰素与拉米夫定序贯α-2b干扰素治疗HBeAg阳性慢性乙型病毒性肝炎患者48周疗效观察  

作　　者：黄飞[1] 任静[1] 杨忠民[1] 

机构地区：[1]湖北省荆州市中心医院感染科,湖北荆州434000

出　　处：《医学与社会》2015年第B06期229-230,共2页Medicine and Society

摘　　要：目的：研究拉米夫定联合α-2b干扰素与拉米夫定序贯α-2b干扰素治疗HBeAg阳性慢性乙型病毒性肝炎患者疗效（HBVDNA水平及HBeAg转换率）有无差异；方法：46例患者随机分为2组，1组为拉米夫定联合α-2b干扰素组，给予拉米夫定100mgqdpo＋α-2b干扰素500万Uihqod治疗48周，1组为拉米夫定序贯α-2b干扰素组。先给予拉米夫定100mgqdp012周，后加用Ⅸ-2b干扰素500万uihqod治疗12周，再单独给予α-2b干扰素500万U ih qod治疗24周；结果：拉米夫定联合α-2b干扰素组和拉米夫定序贯α-2b干扰素组治疗48周时HBV—DNA阴转率为91．3％、87．0％，HBeAg阴转率为21．7％、21．7％，HBeAg血清转换率为21．7％、17．4％；结论：拉米夫定联合α-2b干扰素组和拉米夫定序贯α-2b干扰素组治疗48周时HBVDNA阴转率、HBeAg阴转率、HBeAg血清转换率均无统计学差异，疗效相当。Objective To investigate whether there are some differences between the lamivudine and interferonα-2b and sequential therapy of lamivudine and interferon α-2b in the treatment of patients with HBeAg positive chronic hepatitis B. Method Divide 46 patients into 2 groups randomly,group A were administrated with the lamivudine 100mg qd po ＋ and 5 million u ih qod interferon α-2b for 48 weeks. Another one is the sequential therapy of lamivudine and interferon α-2b - group B. First, give group B the treatment of lamivudi- ne 100mg qd po for 12 weeks,together with the treatment of 12 weeks with 5 million u ih qod interferon a -2b. Then,receive 24 weeks＇ treatment with 5 million u ih qod interferon α-2b alone. Results： The HBV -DNA negative conversion rate was 91.3% in Combination of lantivudine and interferon α-2b and 87.0% in the sequential therapy of lamivudine and interferona -2b seperately. The negative conversion ratio of HBeAg and rate were21.7% and21.7% respectively in Combination of lamivudine and interferon α-2b. while, the sequential therapy of lamivudine and ,nterferon α-2b, the negative conversion ratio of HBeAg and rate were21.7% andl7.4%. Condusion There were no statistically significances between Combination of lamivudine and interferon α-2b and Sequential therapy of lamivudine and interferon α- 2b in terms of the HBV - DNA negative con- version rate, the negative conversion ratio of HBeAg and seroconversion rate. They have the same efficacy

关 键 词：拉米夫定 Α-2B干扰素 HBeAg阳性乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]